IP Library › Granted Patent US 12,472,219
Granted Patent B2
US 12,472,219 · App. 16/924,985 · Granted Nov 18, 2025

Encapsulated cannabinoid formulations for transdermal delivery

Inventors: Christopher G. Witowski (Tampa, FL); Jacqueline L. Salm (Tampa, FL)
Assignee: Nutrae, LLC
A61K36/185A23L2/56A23L33/105A61K9/0014A61K9/0019A61K9/006A61K9/0073A61K9/1075A61K9/7084A61K31/658A61K45/06A61K47/10A23V2002/00A23V2200/242A23V2250/2132
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,472,219
App. No.
16/924,985
Granted
Nov 18, 2025
Kind
B2
Abstract

Preparation of cannabinoid formulations containing: Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigero (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Claims (9)

1 . A method for preparing a cannabinoid composition for transdermal delivery, the method comprising:

a) preparing an oil phase composition comprising:

i) a cannabinoid preparation;

ii) at least one non-ionic surfactant, wherein the non-ionic surfactant comprises a hydrophilic compartment and a hydrophobic compartment; and

iii) at least one co-solvent;

b) preparing a water phase composition comprising:

i) water;

ii) and a stabilizing agent; and

c) mixing the oil phase composition and the water phase composition together to facilitate the formation of micelles within a microemulsion having uni-, bi-, or multi-lamellar structures; wherein said cannabinoid composition is for transdermal delivery, the at least one non-ionic surfactant forms a self-assembling emulsion in a self-emulsifying drug delivery system, wherein the cannabinoid composition is incorporated into a patch comprising a patch reservoir backing film and an adhesive; wherein the patch reservoir contains the cannabinoid composition within the backing film, and affixes to the skin via the adhesive for transdermal delivery of the cannabinoid composition and wherein the patch reservoir has a membrane sealed to the patch reservoir backing film.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: CHICAGO ATLANTIC ADMIN, LLC
To: NUTRAE, LLC
Reel/Frame 074076/0550 →
SECURITY INTEREST Recorded Mar 11, 2026
From: NUTRAE LLC
To: NEEDHAM BANK
Reel/Frame 074042/0522 →
SECURITY INTEREST Recorded Oct 27, 2022
From: NUTRAE, LLC
To: CHICAGO ATLANTIC ADMIN, LLC
Reel/Frame 061558/0704 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2022
From: WITOWSKI, CHRISTOPHER G.; SALM, JACQUELINE L.
To: NUTRAE, LLC
Reel/Frame 061104/0335 →
Continuity (3)
Continuation 16246411 · Jan 11, 2019
Provisional Application 62617003 · Jan 12, 2018
Related Publication 20200338151A1 · Oct 29, 2020
References Cited (51)
US 5891465A · Keller et al. · 1999 [cited by applicant]
US 10709747B2 · Salm et al. · 2020 [cited by applicant]
US 10709748B2 · Witowski et al. · 2020 [cited by applicant]
US 20050266061A1 · Stinchcomb et al. · 2005 [cited by applicant]
US 20100203114A1 · Kwon et al. · 2010 [cited by applicant]
US 20140357708A1 · Murty et al. · 2014 [cited by applicant]
US 20150126595A1 · Smith · 2015 [cited by applicant]
US 20160303039A1 · Smith et al. · 2016 [cited by applicant]
US 20170043932A1 · Byun et al. · 2017 [cited by applicant]
US 20190060225A1 · Mandel et al. · 2019 [cited by applicant]
US 20190110981A1 · Weimann · 2019 [cited by examiner]
US 20190133994A1 · Smith · 2019 [cited by examiner]
US 20190192428A1 · Goskonda et al. · 2019 [cited by applicant]
US 20190216869A1 · Salm et al. · 2019 [cited by applicant]
US 20190216870A1 · Witowski et al. · 2019 [cited by applicant]
US 20200338150A1 · Salm et al. · 2020 [cited by applicant]
US 20200338151A1 · Witowski et al. · 2020 [cited by applicant]
AU 2013213706B2 · 2013 [cited by applicant]
LU 101384B1 · 2020 [cited by applicant]
LU 101385B1 · 2020 [cited by applicant]
WO 200103668A1 · 2001 [cited by applicant]
WO 2002064109A2 · 2002 [cited by applicant]
WO 2012033478A1 · 2012 [cited by applicant]
WO 2015161165A1 · 2015 [cited by applicant]
WO 2015200049A1 · 2015 [cited by applicant]
WO 2016147186A1 · 2016 [cited by applicant]
WO 2019140321A1 · 2019 [cited by applicant]
WO 2019140323A1 · 2019 [cited by applicant]
WO 2019140325A1 · 2019 [cited by applicant]
Griffin (1949), “Classification of Surface-Active Agents by ‘HLB’”, Journal of the Society of Cosmetic Chemists, 1(5): 311-26. [cited by applicant]
Chen et al., “Natural terpenes as penetration enhancers for transdermal drug delivery”, Molecules. 2016, 21, 1709, 21 pages. [cited by applicant]
Esposito et al., “Cannabinoid antagonist in nanostructured lipid carriers (NLC): design, characterization, and in vivo study”, Mater. Sci Eng. 2015, 48, 328-336. [cited by applicant]
Lodzki et al., “Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model”, J. Control. Release. 2003, 93, 377-387. [cited by applicant]
Narang et al., “Stable drug encapsulation in micelles and microemulsions”, Int. J. Pharm. 2007, 345, 9-25. [cited by applicant]
O'Driscoll et al., “Biopharmaceutical challenges associated with with drugs with low aquous solubility—the potential impact of lipid-based formulations”, Adv. Drug Deliv. Rev. 2008, 60, 617-624. [cited by applicant]
Touitou et al., “Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties”, J. Control. Release. 2000, 65, 403-418. [cited by applicant]
Officer Athina Nickitas-Etienne, International Preliminary Report on Patentability for PCT/US2019/013374, date of mailing Jul. 23, 2020; 7 pages. [cited by applicant]
Officer Jose Ruiz Fernandez; International Search Report and Written Opinion; PCT/US2019/013376; date of mailing Mar. 29, 2019; 12 pages. [cited by applicant]
Officer Jose Ruiz Fernandez; International Search Report and Written Opinion; PCT/US2019/013374; date of mailing Mar. 29, 2019; 23 pages. [cited by applicant]
Officer Anita Meacle; International Search Report and Written Opinion; PCT/US2019/013374; date of mailing Apr. 5, 2019; 12 pages. [cited by applicant]
European Patent Office, Examination Report pursuant to Article 94(3) EPC for European Patent Application No. 19703461.4 dated Jul. 8, 2022, 5 pages. [cited by applicant]
European Patent Office, Examination Report pursuant to Article 94(3) EPC for European Patent Application No. 19703462.2 dated Jul. 12, 2022, 6 pages. [cited by applicant]
Israel Patent Office, Notice of Deficiencies for Patent Application 292126 dated Oct. 3, 2022; 4 pages. [cited by applicant]
Israel Patent Office, Notice of Deficiencies for Patent Application 292127 dated Oct. 31, 2022; 4 pages. [cited by applicant]
Australian Patent Office, Examination Report for Australian Patent Application No. 2019206649 dated Oct. 27, 2023, 4 pages. [cited by applicant]
Australian Patent Office, Examination Report for Australian Patent Application No. 2019206651 dated Oct. 27, 2023, 4 pages. [cited by applicant]
Brazilian Patent Office, Examination Report for Brazilian Patent Application No. BR112020014252-2 dated Mar. 14, 2023, 5 pages. [cited by applicant]
Brazilian Patent Office, Examination Report for Brazilian Patent Application No. BR112020014253-0 dated Mar. 14, 2023, 5 pages. [cited by applicant]
European Patent Office, Examination Report pursuant to Article 94(3) EPC for European Patent Application No. 19703461.4 dated May 3, 2023, 5 pages. [cited by applicant]
Israel Patent Office, Notice of Deficiencies for Patent Application 292127 dated Sep. 21, 2023; 5 pages. [cited by applicant]
Israel Patent Office, Notice of Deficiencies for Patent Application 292127 dated Dec. 16, 2024; 4 pages. [cited by applicant]